Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.47 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.47 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.47 |
| ▸ | CBFB | Q13951 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2554377 | 0.85 | ALDH1A1 (0.56) | SMN1; SMN2TDP1ALDH1A1HSD17B10HTT | |
| SCHEMBL29956001 | 0.85 | ALDH1A1 (0.56) | SMN1; SMN2TDP1ALDH1A1HSD17B10HTT | |
| SCHEMBL3788150 | 0.81 | HTT (0.48) | SMN1; SMN2TDP1ALDH1A1HSD17B10HTT | |
| SCHEMBL1889302 | 0.81 | PKM (0.53) | SMN1; SMN2TDP1ALDH1A1HSD17B10HTT | |
| SCHEMBL2336203 | 0.80 | POLB (0.68) | SMN1; SMN2TDP1ALDH1A1HSD17B10HTT | |
| SCHEMBL29990241 | 0.80 | POLB (0.68) | SMN1; SMN2TDP1ALDH1A1HSD17B10HTT | |
| SCHEMBL4547745 | 0.80 | MEN1 (0.49) | SMN1; SMN2TDP1ALDH1A1HSD17B10HTT | |
| SCHEMBL8873149 | 0.80 | ALDH1A1 (0.51) | SMN1; SMN2TDP1ALDH1A1HSD17B10HTT | |
| SCHEMBL864429 | 0.79 | SMN1; SMN2 (0.79) | SMN1; SMN2ALDH1A1HTTL3MBTL1KMT2A | |
| SCHEMBL31349930 | 0.79 | SMN1; SMN2 (0.79) | SMN1; SMN2ALDH1A1HTTL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250362134-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250057817-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-02 | — | — | US | disclosed |
| EP-4001269-A1 | BENZOISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | Amgen Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3974429-A1 | PRECURSORS OF KRAS G12C INHIBITORS | Amgen Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-02-20 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2018-11-22 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-2155717-B1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8202873-B2 | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2155717-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008141020-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMN1; SMN2 3173/4885TDP1 3096/4885ALDH1A1 4162/4885 |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMN1; SMN2 3173/4885TDP1 3096/4885ALDH1A1 4162/4885 |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMN1; SMN2 3163/4885TDP1 2958/4885ALDH1A1 3939/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMN1; SMN2 2904/4885TDP1 3108/4885ALDH1A1 2150/4885 |
| US-20250057817-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMN1; SMN2 3173/4885TDP1 3096/4885ALDH1A1 4162/4885 |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR2C, HTR4 | SMN1; SMN2 2154/4885TDP1 4155/4885ALDH1A1 1205/4885 |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMN1; SMN2 3173/4885TDP1 3096/4885ALDH1A1 4162/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMN1; SMN2 3173/4885TDP1 3096/4885ALDH1A1 4162/4885 |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMN1; SMN2 3173/4885TDP1 3096/4885ALDH1A1 4162/4885 |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMN1; SMN2 3173/4885TDP1 3096/4885ALDH1A1 4162/4885 |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMN1; SMN2 3173/4885TDP1 3096/4885ALDH1A1 4162/4885 |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMN1; SMN2 2927/4885TDP1 2942/4885ALDH1A1 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.